We thank Matthew Walton (Research Training Fellow in Systematic Review) for his contribution to the section on registry data. We also thank the manufacturers for responding to our requests for additional data.
Contributions of authors
Ana Duarte (Research Fellow, Health Economics) contributed to the protocol, the development of the economic model, the review of the economic analyses, the interpretation of the results and the writing of the report.
Teumzghi Mebrahtu (Research Fellow, Evidence Synthesis) contributed to the protocol, study selection, data extraction, the validity assessments and synthesis of the included studies, the interpretation of the results and the writing of the report.
Pedro Saramago Goncalves (Research Fellow, Health Economics) contributed to the protocol and conducted the network meta-analyses. He also contributed to the interpretation of the results and the writing of the report.
Melissa Harden (Information Specialist) developed the search strategies, conducted a range of searches to locate studies and wrote the sections of the report relating to the literature searches.
Ruth Murphy (Consultant Dermatologist, Paediatric Dermatology) provided expert clinical advice, contributed to the protocol and the interpretation of the results and commented on drafts of the report.
Stephen Palmer (Professor of Health Economics) contributed to the protocol, advised on the economic analysis and the interpretation of the results and commented on drafts of the report.
Nerys Woolacott (Reader in Health Technology Assessment) contributed to the protocol, advised on the clinical evidence review and the interpretation of the results and commented on drafts of the report.
Mark Rodgers (Research Fellow, Evidence Synthesis) contributed to the protocol, study selection, data extraction and the validity assessments and synthesis of the included studies. He also contributed to the interpretation of the results and the writing of the report. He took overall responsibility for the clinical effectiveness section.
Claire Rothery (Senior Research Fellow, Health Economics) had overall responsibility for the cost-effectiveness sections. She contributed to the development of the protocol, the network meta-analyses, the economic model and the economic analyses. She also contributed to the interpretation of the results and the writing of the report.
Data sharing statement
This report uses published primary research and other publicly available data, supplemented by evidence provided by the manufacturers of adalimumab (AbbVie) and ustekinumab (Janssen Biotech, Inc.). The full list of data sources is provided in the appendices. Further information can be obtained from the corresponding author.
Disclaimers
This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.
